On Demand Webinar: Lipids – from statins to PCSK9i and beyond
In the second of our 2022 ABCD webinar series, please join Dr Derek Connolly to discuss the future horizons in hyperlipidaemia
Cardiovascular disease is the worlds biggest killer in terms of years of life lost. We know that cholesterol is responsible for around 7% of all deaths in United Kingdom. We now have the tools to lower cholesterol and 2021 to 2022 has shown the greatest change in the methodologies of lipid reduction thus far. Dr Connolly will be reviewing all of the evidence that has emerged in the last two years.
This meeting has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 1 category 1 (external) credit (ref: 1362
Speakers
-
Dr. Ansu Basu
Consultant Physician
Dr Ansu Basu works as a Consultant Physician and Endocrinologist at Sandwell and West Birmingham Hospital NHS Trust. He has previously served as Clinical Director for Diabetes and Endocrinology and is currently Deputy Medical Director responsible for developing PHM-based model of care working closely with Primary Care Networks. His clinical academic interests include cardiovascular disease and diabetes, diabetic retinopathy, diabetes in pregnancy and mineral metabolism. He has a keen interest in thyroid ultrasonography and set up a near-patient service in out-patient clinics. He is actively involved in undergraduate and postgraduate training and is an Honorary Senior Lecturer at the University of Birmingham. He completed his MD on Automated imaging in Diabetic Retinopathy using Artificial Neural Networks from the University of Newcastle upon Tyne and has published widely in endocrinology and diabetes. He takes a keen interest in the use of data analytics to improve healthcare delivery.
-
Professor Derek Connolly
Professor Derek Connolly is a Consultant Cardiologist and Honorary Professor at Birmingham City Hospital, Birmingham UK. He trained in Cambridge, London, Edinburgh and San Diego where he was a Carnegie Scholar. He has a first class degree in Pharmacology from the University of Edinburgh where he was the Brunton medallist and Keasbey Bursary holder. His PhD in molecular cardiology is from the University of Cambridge. He is the Chief or Primary Investigator of multiple large trials in Cardiovascular medicine. He developed one of the UKs first primary angioplasty programmes, and one of the UKs largest cardiac CT programmes. He is the ICB lead in cardiac care for the Black Country and is on the council of the UK Primary Care Cardiovascular Society.
